Roche to Acquire PathAI in Push to Automate Pathology Diagnostics
Roche has agreed to acquire PathAI, a Boston-based digital pathology company, in a deal expected to close in the second half of 2026. The acquisition builds on a partnership that began in 2021 and expanded in 2024 to include AI-powered companion diagnostic algorithms.
PathAI's core product is AISight, an image management system that converts physical tissue slides into high-resolution digital images and applies AI analysis to automate pathology workflows. Roche plans to integrate this software into its oncology diagnostic platforms and scale it globally.
The deal addresses a practical problem in pathology labs: manual slide review is slow and labor-intensive. Digital pathology with AI can speed diagnosis and free pathologists to focus on complex cases rather than routine screening.
Why This Matters for Diagnostics
Roche's Diagnostics division already leads in companion diagnostics-tests that identify which patients will respond to specific drugs. PathAI's strength in clinical trial support and biomarker discovery complements this position.
Together, the companies say they can accelerate drug development by identifying new biomarkers and drug targets faster. For patients, the outcome is narrower, more precise treatment recommendations rather than broad interventions.
Matt Sause, CEO of Roche Diagnostics, said the combination will "deliver better insights for physicians and potentially better outcomes for patients worldwide." Andy Beck, PathAI's co-founder and CEO, added that Roche's infrastructure will allow the company to "realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed."
What Happens Next
Once the acquisition closes, PathAI will become part of Roche's Diagnostics division. The company has not disclosed financial terms.
For healthcare professionals managing diagnostic workflows, the move signals that AI-driven automation in pathology is moving from pilot projects to production systems backed by major infrastructure players.
Learn more about AI for Healthcare and how machine learning is reshaping clinical diagnostics.
Your membership also unlocks:
